Class Action Lawsuit Adds Legal Risk to Nektar's Critical Phase 3 Funding Push

What happened

A class action lawsuit has been filed against Nektar Therapeutics and certain officers, alleging violations of federal securities laws during the period from February 26 to December 25, 2025. This timeframe overlaps with NKTR's pivotal Phase 2b data releases for rezpegaldesleukin in atopic dermatitis, FDA alignment on Phase 3 trials, and the announcement of a $300M equity offering. The allegations likely center on disclosures or omissions related to clinical durability claims or financing risks, as highlighted in filings showing responder-enriched data and funding sensitivity. During this period, NKTR's stock experienced significant volatility, rising from around $10 to over $60, reflecting market optimism tempered by execution dependencies. This legal action introduces reputational and financial uncertainty just as the company navigates its critical $300M raise and Q2 2026 Phase 3 start.

Implication

The class action lawsuit introduces a legal overhang that may deter participation in NKTR's $300M equity offering, potentially forcing unfavorable terms or delays. It invites scrutiny of past disclosures, particularly around the durability of Phase 2b data and reliance on responder-enriched cohorts, which could undermine investor confidence. If the lawsuit progresses, it could strain management's credibility and complicate future capital raises, impacting cash runway for Phase 3 trials. This adds a new layer of risk beyond operational execution, such as manufacturing comparability and trial timing, already flagged in the DeepValue report. Consequently, investors should reassess the probability-weighted outcomes, as legal uncertainties amplify the downside in an already binary investment case.

Thesis delta

The lawsuit does not change the core clinical or operational thesis but introduces incremental legal and financing risks that could impair NKTR's near-term catalysts. Previously, the thesis hinged on clean financing terms and Phase 3 initiation; now, investor sentiment and potential legal liabilities must be factored into the risk assessment. This reinforces the 'WAIT' rating by highlighting how external pressures could disrupt capital access and execution momentum.